Share this article
Share this article
INDIANAPOLIS, March 17, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio
® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC). The PRO analysis included patients in both arms of the study and measured their experiences with side effects, symptoms, and health-related quality of life, in those receiving Verzenio plus ET versus ET alone. In one analysis, the PRO data indicated that most patients (approximately 70-75%) in both arms reported being bothered a little bit or not at all by treatment-related side effects. This analysis revealed the addition of Verzenio to ET did not result in a clinically meaningful difference in patients reporting being bothered by treatment side effect
Eli Lilly names new chief ethics and compliance officer complianceweek.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from complianceweek.com Daily Mail and Mail on Sunday newspapers.
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer
Preclinical characterization data will be presented for oral SERD, BCL2 inhibitor, next-generation KRAS-G12C, and RET inhibitors
News provided by
Share this article
Share this article
INDIANAPOLIS, March 10, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. During the meeting, Lilly Oncology will present data from a study exploring safety and efficacy of its selective RET-kinase inhibitor Retevmo
/PRNewswire/ Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021. Patrik Jonsson,.
/PRNewswire/ The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and.